English

BIOADAPTIVES, INC.

EDGAR

BDPT Quarterly report (10-Q) · filed 2026-08-19

Annual consolidated revenue for 2025: about USD 18.28K, using the latest reported figures. The previous period, 2024, was about USD 12.67K.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

4.99 thousand USD

2026 Q2 · USD

Exact inputs and evidence

Revenue: 4988 USD Source

Operating margin

-3,953.01%

2026 Q2 · %

Exact inputs and evidence

Operating Income: -197176 USD Source
Revenue: 4988 USD Source

Operating cash flow

-44.4 thousand USD

2026 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -129224 USD Source
Operating Cash Flow: -84839 USD Source

Cash and cash equivalents: 215 thousand USD 2025-12-31 Source
Exact value

215205 USD
Long-term debt including current maturities: Not available
Shares outstanding: 36.6 million shares 2026-06-30 Source
Exact value

36595174 shares

Reported share-count change

267.84% · 26.6 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

9948725 shares · 2025-06-30· Source
36595174 shares · 2026-06-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

25.6 thousand USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Revenue: 4632 USD · 2025-07-01 – 2025-09-30 Source
Revenue: 18278 USD · 2025-01-01 – 2025-12-31 Source
Revenue: 7851 USD · 2025-01-01 – 2025-09-30 Source
Revenue: 5514 USD · 2026-01-01 – 2026-03-31 Source
Revenue: 4988 USD · 2026-04-01 – 2026-06-30 Source

Net income

-1.16 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Net income: -379502 USD · 2025-07-01 – 2025-09-30 Source
Net income: -1557898 USD · 2025-01-01 – 2025-12-31 Source
Net income: -734552 USD · 2025-01-01 – 2025-09-30 Source
Net income: -111086 USD · 2026-01-01 – 2026-03-31 Source
Net income: 150090 USD · 2026-04-01 – 2026-06-30 Source

Operating cash flow

-436 thousand USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -360197 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -208888 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -516025 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -360197 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -84839 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -129224 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -84839 USD · 2026-01-01 – 2026-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-08-19.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 7 of 11 periods available· newest 2025-12-31
Operating income: 5 of 11 periods available· newest 2025-12-31
Net income: 9 of 11 periods available· newest 2025-12-31
Operating cash flow: 9 of 11 periods available· newest 2025-12-31
Capital expenditure: 2 of 11 periods available· newest 2025-12-31
Total assets: 7 of 11 periods available· newest 2025-12-31
Total liabilities: 7 of 11 periods available· newest 2025-12-31
Current assets: 7 of 11 periods available· newest 2025-12-31
Current liabilities: 7 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 7 of 11 periods available· newest 2025-12-31
long term debt: No compatible figures in this window
Shares outstanding: 7 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+44.3%

Prior period

USD 12,669

2024-01-01 – 2024-12-31
Current period

USD 18,278

2025-01-01 – 2025-12-31

Exact inputs and evidence

18278 − 12669 = 5609 USD

12669 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
18278 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · BIOADAPTIVES, INC. · 2025-12-31 BIOADAPTIVES, INC. (edgar:1575142) Year-over-year change in Revenue: 5609 USD Concept: fundies:Revenue Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T13:14:46Z Snapshot: 19ed27ed0d062779455f6fbc3e021cde2c84c8139c2c05350a9ef8e60485350e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1575142?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 18278 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1575142/000164033426000718/bdpt_10k.htm#290558 Filing: 000164033426000718 Input fundies:Revenue: 12669 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1575142/000164033426000718/bdpt_10k.htm#291124 Filing: 000164033426000718
The citation records this snapshot. The page link may show a newer release later.
Net income
−USD 658,737

Prior period

−USD 899,161

2024-01-01 – 2024-12-31
Current period

−USD 1.56 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-1557898 − -899161 = -658737 USD

-899161 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-1557898 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · BIOADAPTIVES, INC. · 2025-12-31 BIOADAPTIVES, INC. (edgar:1575142) Year-over-year change in Net income: -658737 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T13:14:46Z Snapshot: 19ed27ed0d062779455f6fbc3e021cde2c84c8139c2c05350a9ef8e60485350e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1575142?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -1557898 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1575142/000164033426000718/bdpt_10k.htm#520471 Filing: 000164033426000718 Input fundies:NetIncome: -899161 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1575142/000164033426000718/bdpt_10k.htm#442092 Filing: 000164033426000718
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 266,508

Prior period

−USD 249,517

2024-01-01 – 2024-12-31
Current period

−USD 516,025

2025-01-01 – 2025-12-31

Exact inputs and evidence

-516025 − -249517 = -266508 USD

-249517 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-516025 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · BIOADAPTIVES, INC. · 2025-12-31 BIOADAPTIVES, INC. (edgar:1575142) Year-over-year change in Operating cash flow: -266508 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T13:14:46Z Snapshot: 19ed27ed0d062779455f6fbc3e021cde2c84c8139c2c05350a9ef8e60485350e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1575142?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -516025 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1575142/000164033426000718/bdpt_10k.htm#565280 Filing: 000164033426000718 Input fundies:OperatingCashFlow: -249517 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1575142/000164033426000718/bdpt_10k.htm#565891 Filing: 000164033426000718
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
+USD 18,000

Prior period

USD 0

2024-01-01 – 2024-12-31
Current period

USD 18,000

2025-01-01 – 2025-12-31

Exact inputs and evidence

18000 − 0 = 18000 USD

0 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
18000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · BIOADAPTIVES, INC. · 2025-12-31 BIOADAPTIVES, INC. (edgar:1575142) Year-over-year change in Capital expenditure: 18000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T13:14:46Z Snapshot: 19ed27ed0d062779455f6fbc3e021cde2c84c8139c2c05350a9ef8e60485350e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1575142?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 18000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1575142/000164033426000718/bdpt_10k.htm#569053 Filing: 000164033426000718 Input fundies:CapitalExpenditure: 0 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1575142/000164033426000718/bdpt_10k.htm#569723 Filing: 000164033426000718
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2025 2025-01-01 – 2025-12-31

Revenue USD 18,278 100% of revenue
Cost of revenue USD 5,781 32% of revenue
Operating expenses USD 1.05 million 5,770% of revenue
Operating income −USD 1.04 million −5,702% of revenue
Tax, interest and other Derived USD 515,725 2,822% of revenue
Net income −USD 1.56 million −8,523% of revenue

Cash

Operating cash flow −USD 516,025 −2,823% of revenue
Capital expenditure USD 18,000 98% of revenue
Free cash flow Derived −USD 534,025 −2,922% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2019 Not shown: operating income or net income is not reported.
2020 Not shown: operating income or net income is not reported.
2021 Not shown: operating income or net income is not reported.
2022 Operating loss: operating costs were 2,556% of revenue.
2023 Operating loss: operating costs were 901% of revenue.
2024 Operating loss: operating costs were 4,852% of revenue.
2025 Operating loss: operating costs were 5,802% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2019 2019-01-01 – 2019-12-31	9934	Unavailable	Unavailable	Unavailable	-238927	Unavailable	Source 2019-01-01 – 2019-12-31: 9934 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: -238927 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: -168120 USD Inspect Operating Cash Flow Open source
2020 2020-01-01 – 2020-12-31	16327	Unavailable	Unavailable	Unavailable	-847244	Unavailable	Source 2020-01-01 – 2020-12-31: 16327 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -847244 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: -106889 USD Inspect Operating Cash Flow Open source
2021 2021-01-01 – 2021-12-31	19776	Unavailable	Unavailable	Unavailable	-1049948	Unavailable	Source 2021-01-01 – 2021-12-31: 19776 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -1049948 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -158651 USD Inspect Operating Cash Flow Open source
2022 2022-01-01 – 2022-12-31	17176	439076 Derived	-421900	473670 Derived	-895570	Unavailable	Source 2022-01-01 – 2022-12-31: 17176 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -421900 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -895570 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: -227259 USD Inspect Operating Cash Flow Open source
2023 2023-01-01 – 2023-12-31	28565	257486 Derived	-228921	483545 Derived	-712466	Unavailable	Source 2023-01-01 – 2023-12-31: 28565 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -228921 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -712466 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: -223773 USD Inspect Operating Cash Flow Open source
2024 2024-01-01 – 2024-12-31	12669	614759 Derived	-602090	297071 Derived	-899161	-249517 Derived	Source 2024-01-01 – 2024-12-31: 12669 USD Inspect Revenue Open source 2024-01-01 – 2024-12-31: -602090 USD Inspect Operating Income Open source 2024-01-01 – 2024-12-31: -899161 USD Inspect Net Income Open source 2024-01-01 – 2024-12-31: -249517 USD Inspect Operating Cash Flow Open source 2024-01-01 – 2024-12-31: 0 USD Inspect Capital Expenditure Open source
2025 2025-01-01 – 2025-12-31	18278	1060451 Derived	-1042173	515725 Derived	-1557898	-534025 Derived	Source 2025-01-01 – 2025-12-31: 18278 USD Inspect Revenue Open source 2025-01-01 – 2025-12-31: -1042173 USD Inspect Operating Income Open source 2025-01-01 – 2025-12-31: -1557898 USD Inspect Net Income Open source 2025-01-01 – 2025-12-31: -516025 USD Inspect Operating Cash Flow Open source 2025-01-01 – 2025-12-31: 18000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 18.3K 2025

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20192019-12-31	Revenue	9934	Revenue: 9934 Open source
20202020-12-31	Revenue	16327	Revenue: 16327 Open source
20212021-12-31	Revenue	19776	Revenue: 19776 Open source
20222022-12-31	Revenue	17176	Revenue: 17176 Open source
20232023-12-31	Revenue	28565	Revenue: 28565 Open source
20242024-12-31	Revenue	12669	Revenue: 12669 Open source
20252025-12-31	Revenue	18278	Revenue: 18278 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

44.3% 2025

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20192019-12-31	Year over year	No prior comparable period	Revenue: 9934 Open source
20202020-12-31	Year over year	64.4%	Revenue: 16327 Open source Revenue: 9934 Open source
20212021-12-31	Year over year	21.1%	Revenue: 19776 Open source Revenue: 16327 Open source
20222022-12-31	Year over year	-13.1%	Revenue: 17176 Open source Revenue: 19776 Open source
20232023-12-31	Year over year	66.3%	Revenue: 28565 Open source Revenue: 17176 Open source
20242024-12-31	Year over year	-55.6%	Revenue: 12669 Open source Revenue: 28565 Open source
20252025-12-31	Year over year	44.3%	Revenue: 18278 Open source Revenue: 12669 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -5,701.8% 2025

Net margin -8,523.4% 2025

Free cash flow margin -2,921.7% 2025

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
2019-12-31	Operating margin	Not reported	Revenue: 9934 Open source
2020-12-31	Operating margin	Not reported	Revenue: 16327 Open source
2021-12-31	Operating margin	Not reported	Revenue: 19776 Open source
20222022-12-31	Operating margin	-2,456.3%	Operating Income: -421900 Open source Revenue: 17176 Open source
20232023-12-31	Operating margin	-801.4%	Operating Income: -228921 Open source Revenue: 28565 Open source
20242024-12-31	Operating margin	-4,752.5%	Operating Income: -602090 Open source Revenue: 12669 Open source
20252025-12-31	Operating margin	-5,701.8%	Operating Income: -1042173 Open source Revenue: 18278 Open source
20192019-12-31	Net margin	-2,405.1%	Net Income: -238927 Open source Revenue: 9934 Open source
20202020-12-31	Net margin	-5,189.2%	Net Income: -847244 Open source Revenue: 16327 Open source
20212021-12-31	Net margin	-5,309.2%	Net Income: -1049948 Open source Revenue: 19776 Open source
20222022-12-31	Net margin	-5,214.1%	Net Income: -895570 Open source Revenue: 17176 Open source
20232023-12-31	Net margin	-2,494.2%	Net Income: -712466 Open source Revenue: 28565 Open source
20242024-12-31	Net margin	-7,097.3%	Net Income: -899161 Open source Revenue: 12669 Open source
20252025-12-31	Net margin	-8,523.4%	Net Income: -1557898 Open source Revenue: 18278 Open source
20192019-12-31	Free cash flow margin	Not reported	Revenue: 9934 Open source Operating Cash Flow: -168120 Open source
20202020-12-31	Free cash flow margin	Not reported	Revenue: 16327 Open source Operating Cash Flow: -106889 Open source
20212021-12-31	Free cash flow margin	Not reported	Revenue: 19776 Open source Operating Cash Flow: -158651 Open source
20222022-12-31	Free cash flow margin	Not reported	Revenue: 17176 Open source Operating Cash Flow: -227259 Open source
20232023-12-31	Free cash flow margin	Not reported	Revenue: 28565 Open source Operating Cash Flow: -223773 Open source
20242024-12-31	Free cash flow margin	-1,969.5%	Revenue: 12669 Open source Operating Cash Flow: -249517 Open source Capital Expenditure: 0 Open source
20252025-12-31	Free cash flow margin	-2,921.7%	Revenue: 18278 Open source Operating Cash Flow: -516025 Open source Capital Expenditure: 18000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -516K 2025

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20192019-12-31	Operating cash flow	-168120	Operating Cash Flow: -168120 Open source
20202020-12-31	Operating cash flow	-106889	Operating Cash Flow: -106889 Open source
20212021-12-31	Operating cash flow	-158651	Operating Cash Flow: -158651 Open source
20222022-12-31	Operating cash flow	-227259	Operating Cash Flow: -227259 Open source
20232023-12-31	Operating cash flow	-223773	Operating Cash Flow: -223773 Open source
20242024-12-31	Operating cash flow	-249517	Operating Cash Flow: -249517 Open source
20252025-12-31	Operating cash flow	-516025	Operating Cash Flow: -516025 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -534K 2025

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20192019-12-31	Free cash flow	Unavailable	Operating Cash Flow: -168120 Open source
20202020-12-31	Free cash flow	Unavailable	Operating Cash Flow: -106889 Open source
20212021-12-31	Free cash flow	Unavailable	Operating Cash Flow: -158651 Open source
20222022-12-31	Free cash flow	Unavailable	Operating Cash Flow: -227259 Open source
20232023-12-31	Free cash flow	Unavailable	Operating Cash Flow: -223773 Open source
20242024-12-31	Free cash flow	-249517	Operating Cash Flow: -249517 Open source Capital Expenditure: 0 Open source
20252025-12-31	Free cash flow	-534025	Operating Cash Flow: -516025 Open source Capital Expenditure: 18000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

1,042.9% 2025

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20192019-12-31	Liabilities / assets	3,568.7%	Total Liabilities: 864089 Open source Total Assets: 24213 Open source
20202020-12-31	Liabilities / assets	7,416.1%	Total Liabilities: 1397631 Open source Total Assets: 18846 Open source
20212021-12-31	Liabilities / assets	835.6%	Total Liabilities: 1241624 Open source Total Assets: 148585 Open source
20222022-12-31	Liabilities / assets	3,990%	Total Liabilities: 1488815 Open source Total Assets: 37314 Open source
20232023-12-31	Liabilities / assets	1,683.3%	Total Liabilities: 1750629 Open source Total Assets: 103998 Open source
20242024-12-31	Liabilities / assets	659%	Total Liabilities: 1725803 Open source Total Assets: 261885 Open source
20252025-12-31	Liabilities / assets	1,042.9%	Total Liabilities: 2355957 Open source Total Assets: 225901 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

0.09× 2025

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20192019-12-31	Current assets / current liabilities	0.03×	Current Assets: 24213 Open source Current Liabilities: 864089 Open source
20202020-12-31	Current assets / current liabilities	0.01×	Current Assets: 18846 Open source Current Liabilities: 1397631 Open source
20212021-12-31	Current assets / current liabilities	0.07×	Current Assets: 88876 Open source Current Liabilities: 1241624 Open source
20222022-12-31	Current assets / current liabilities	0.02×	Current Assets: 34324 Open source Current Liabilities: 1488815 Open source
20232023-12-31	Current assets / current liabilities	0.05×	Current Assets: 88557 Open source Current Liabilities: 1750629 Open source
20242024-12-31	Current assets / current liabilities	0.15×	Current Assets: 261885 Open source Current Liabilities: 1725803 Open source
20252025-12-31	Current assets / current liabilities	0.09×	Current Assets: 211901 Open source Current Liabilities: 2355957 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2015 2015-01-01 – 2015-12-31	−USD 227,432 Exact value Exact value: -227432 USD 2015-01-01 – 2015-12-31: -227432 USD Inspect Net Income Open source Share or cite Citation for Net Income · BIOADAPTIVES, INC. · 2015-12-31 BIOADAPTIVES, INC. (edgar:1575142) Net Income: -227432 USD Concept: fundies:NetIncome Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T13:14:46Z Snapshot: 19ed27ed0d062779455f6fbc3e021cde2c84c8139c2c05350a9ef8e60485350e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1575142/explain?concept=fundies%3ANetIncome&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:NetIncome: -227432 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1575142/000164033416000961/bdpt-20151231.xml#49277 Filing: 000164033416000961 The citation records this snapshot. The page link may show a newer release later.	−USD 72 Exact value Exact value: -72 USD 2015-01-01 – 2015-12-31: -72 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · BIOADAPTIVES, INC. · 2015-12-31 BIOADAPTIVES, INC. (edgar:1575142) Operating Cash Flow: -72 USD Concept: fundies:OperatingCashFlow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T13:14:46Z Snapshot: 19ed27ed0d062779455f6fbc3e021cde2c84c8139c2c05350a9ef8e60485350e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1575142/explain?concept=fundies%3AOperatingCashFlow&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -72 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1575142/000164033416000961/bdpt-20151231.xml#53211 Filing: 000164033416000961 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2018 2018-01-01 – 2018-12-31	−USD 1.41 million Exact value Exact value: -1406663 USD 2018-01-01 – 2018-12-31: -1406663 USD Inspect Net Income Open source Share or cite Citation for Net Income · BIOADAPTIVES, INC. · 2018-12-31 BIOADAPTIVES, INC. (edgar:1575142) Net Income: -1406663 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T13:14:46Z Snapshot: 19ed27ed0d062779455f6fbc3e021cde2c84c8139c2c05350a9ef8e60485350e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1575142/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -1406663 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1575142/000164033420001156/bdpt-20191231.xml#67449 Filing: 000164033420001156 The citation records this snapshot. The page link may show a newer release later.	−USD 420,145 Exact value Exact value: -420145 USD 2018-01-01 – 2018-12-31: -420145 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · BIOADAPTIVES, INC. · 2018-12-31 BIOADAPTIVES, INC. (edgar:1575142) Operating Cash Flow: -420145 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T13:14:46Z Snapshot: 19ed27ed0d062779455f6fbc3e021cde2c84c8139c2c05350a9ef8e60485350e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1575142/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -420145 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1575142/000164033420001156/bdpt-20191231.xml#90694 Filing: 000164033420001156 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2019 2019-01-01 – 2019-12-31	−USD 238,927 Exact value Exact value: -238927 USD 2019-01-01 – 2019-12-31: -238927 USD Inspect Net Income Open source Share or cite Citation for Net Income · BIOADAPTIVES, INC. · 2019-12-31 BIOADAPTIVES, INC. (edgar:1575142) Net Income: -238927 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T13:14:46Z Snapshot: 19ed27ed0d062779455f6fbc3e021cde2c84c8139c2c05350a9ef8e60485350e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1575142/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -238927 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1575142/000164033421000706/bdpt-20201231.xml#70276 Filing: 000164033421000706 The citation records this snapshot. The page link may show a newer release later.	−USD 168,120 Exact value Exact value: -168120 USD 2019-01-01 – 2019-12-31: -168120 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · BIOADAPTIVES, INC. · 2019-12-31 BIOADAPTIVES, INC. (edgar:1575142) Operating Cash Flow: -168120 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T13:14:46Z Snapshot: 19ed27ed0d062779455f6fbc3e021cde2c84c8139c2c05350a9ef8e60485350e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1575142/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -168120 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1575142/000164033421000706/bdpt-20201231.xml#86475 Filing: 000164033421000706 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2020 2020-01-01 – 2020-12-31	−USD 847,244 Exact value Exact value: -847244 USD 2020-01-01 – 2020-12-31: -847244 USD Inspect Net Income Open source Share or cite Citation for Net Income · BIOADAPTIVES, INC. · 2020-12-31 BIOADAPTIVES, INC. (edgar:1575142) Net Income: -847244 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T13:14:46Z Snapshot: 19ed27ed0d062779455f6fbc3e021cde2c84c8139c2c05350a9ef8e60485350e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1575142/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -847244 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1575142/000164033422000689/bdpt_10k.htm#440233 Filing: 000164033422000689 The citation records this snapshot. The page link may show a newer release later.	−USD 106,889 Exact value Exact value: -106889 USD 2020-01-01 – 2020-12-31: -106889 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · BIOADAPTIVES, INC. · 2020-12-31 BIOADAPTIVES, INC. (edgar:1575142) Operating Cash Flow: -106889 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T13:14:46Z Snapshot: 19ed27ed0d062779455f6fbc3e021cde2c84c8139c2c05350a9ef8e60485350e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1575142/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -106889 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1575142/000164033422000689/bdpt_10k.htm#459390 Filing: 000164033422000689 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2021 2021-01-01 – 2021-12-31	−USD 1.05 million Exact value Exact value: -1049948 USD 2021-01-01 – 2021-12-31: -1049948 USD Inspect Net Income Open source Share or cite Citation for Net Income · BIOADAPTIVES, INC. · 2021-12-31 BIOADAPTIVES, INC. (edgar:1575142) Net Income: -1049948 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T13:14:46Z Snapshot: 19ed27ed0d062779455f6fbc3e021cde2c84c8139c2c05350a9ef8e60485350e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1575142/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -1049948 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1575142/000164033423000532/bdpt_10k.htm#465566 Filing: 000164033423000532 The citation records this snapshot. The page link may show a newer release later.	−USD 158,651 Exact value Exact value: -158651 USD 2021-01-01 – 2021-12-31: -158651 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · BIOADAPTIVES, INC. · 2021-12-31 BIOADAPTIVES, INC. (edgar:1575142) Operating Cash Flow: -158651 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T13:14:46Z Snapshot: 19ed27ed0d062779455f6fbc3e021cde2c84c8139c2c05350a9ef8e60485350e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1575142/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -158651 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1575142/000164033423000532/bdpt_10k.htm#484575 Filing: 000164033423000532 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2022 2022-01-01 – 2022-12-31	−USD 895,570 Exact value Exact value: -895570 USD 2022-01-01 – 2022-12-31: -895570 USD Inspect Net Income Open source Share or cite Citation for Net Income · BIOADAPTIVES, INC. · 2022-12-31 BIOADAPTIVES, INC. (edgar:1575142) Net Income: -895570 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T13:14:46Z Snapshot: 19ed27ed0d062779455f6fbc3e021cde2c84c8139c2c05350a9ef8e60485350e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1575142/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -895570 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1575142/000164033424000602/bdpt_10k.htm#406001 Filing: 000164033424000602 The citation records this snapshot. The page link may show a newer release later.	−USD 227,259 Exact value Exact value: -227259 USD 2022-01-01 – 2022-12-31: -227259 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · BIOADAPTIVES, INC. · 2022-12-31 BIOADAPTIVES, INC. (edgar:1575142) Operating Cash Flow: -227259 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T13:14:46Z Snapshot: 19ed27ed0d062779455f6fbc3e021cde2c84c8139c2c05350a9ef8e60485350e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1575142/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -227259 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1575142/000164033424000602/bdpt_10k.htm#492120 Filing: 000164033424000602 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2023 2023-01-01 – 2023-12-31	−USD 712,466 Exact value Exact value: -712466 USD 2023-01-01 – 2023-12-31: -712466 USD Inspect Net Income Open source Share or cite Citation for Net Income · BIOADAPTIVES, INC. · 2023-12-31 BIOADAPTIVES, INC. (edgar:1575142) Net Income: -712466 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T13:14:46Z Snapshot: 19ed27ed0d062779455f6fbc3e021cde2c84c8139c2c05350a9ef8e60485350e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1575142/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -712466 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1575142/000164033425000660/bdpt_10k.htm#399362 Filing: 000164033425000660 The citation records this snapshot. The page link may show a newer release later.	−USD 223,773 Exact value Exact value: -223773 USD 2023-01-01 – 2023-12-31: -223773 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · BIOADAPTIVES, INC. · 2023-12-31 BIOADAPTIVES, INC. (edgar:1575142) Operating Cash Flow: -223773 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T13:14:46Z Snapshot: 19ed27ed0d062779455f6fbc3e021cde2c84c8139c2c05350a9ef8e60485350e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1575142/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -223773 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1575142/000164033425000660/bdpt_10k.htm#531239 Filing: 000164033425000660 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2024 2024-01-01 – 2024-12-31	−USD 899,161 Exact value Exact value: -899161 USD 2024-01-01 – 2024-12-31: -899161 USD Inspect Net Income Open source Share or cite Citation for Net Income · BIOADAPTIVES, INC. · 2024-12-31 BIOADAPTIVES, INC. (edgar:1575142) Net Income: -899161 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T13:14:46Z Snapshot: 19ed27ed0d062779455f6fbc3e021cde2c84c8139c2c05350a9ef8e60485350e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1575142/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -899161 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1575142/000164033426000718/bdpt_10k.htm#442092 Filing: 000164033426000718 The citation records this snapshot. The page link may show a newer release later.	−USD 249,517 Exact value Exact value: -249517 USD 2024-01-01 – 2024-12-31: -249517 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · BIOADAPTIVES, INC. · 2024-12-31 BIOADAPTIVES, INC. (edgar:1575142) Operating Cash Flow: -249517 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T13:14:46Z Snapshot: 19ed27ed0d062779455f6fbc3e021cde2c84c8139c2c05350a9ef8e60485350e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1575142/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -249517 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1575142/000164033426000718/bdpt_10k.htm#565891 Filing: 000164033426000718 The citation records this snapshot. The page link may show a newer release later.	USD 0 Exact value Exact value: 0 USD 2024-01-01 – 2024-12-31: 0 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · BIOADAPTIVES, INC. · 2024-12-31 BIOADAPTIVES, INC. (edgar:1575142) Capital Expenditure: 0 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T13:14:46Z Snapshot: 19ed27ed0d062779455f6fbc3e021cde2c84c8139c2c05350a9ef8e60485350e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1575142/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 0 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1575142/000164033426000718/bdpt_10k.htm#569723 Filing: 000164033426000718 The citation records this snapshot. The page link may show a newer release later.	−USD 249,517 Calculation and evidence -249517 − 0 USD Exact free cash flow: -249517 USD 2024-01-01 – 2024-12-31: -249517 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 0 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · BIOADAPTIVES, INC. · 2024-12-31 BIOADAPTIVES, INC. (edgar:1575142) Free cash flow: -249517 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T13:14:46Z Snapshot: 19ed27ed0d062779455f6fbc3e021cde2c84c8139c2c05350a9ef8e60485350e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1575142?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -249517 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1575142/000164033426000718/bdpt_10k.htm#565891 Filing: 000164033426000718 Input fundies:CapitalExpenditure: 0 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1575142/000164033426000718/bdpt_10k.htm#569723 Filing: 000164033426000718 The citation records this snapshot. The page link may show a newer release later.
2025 2025-01-01 – 2025-12-31	−USD 1.56 million Exact value Exact value: -1557898 USD 2025-01-01 – 2025-12-31: -1557898 USD Inspect Net Income Open source Share or cite Citation for Net Income · BIOADAPTIVES, INC. · 2025-12-31 BIOADAPTIVES, INC. (edgar:1575142) Net Income: -1557898 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T13:14:46Z Snapshot: 19ed27ed0d062779455f6fbc3e021cde2c84c8139c2c05350a9ef8e60485350e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1575142/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: -1557898 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1575142/000164033426000718/bdpt_10k.htm#520471 Filing: 000164033426000718 The citation records this snapshot. The page link may show a newer release later.	−USD 516,025 Exact value Exact value: -516025 USD 2025-01-01 – 2025-12-31: -516025 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · BIOADAPTIVES, INC. · 2025-12-31 BIOADAPTIVES, INC. (edgar:1575142) Operating Cash Flow: -516025 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T13:14:46Z Snapshot: 19ed27ed0d062779455f6fbc3e021cde2c84c8139c2c05350a9ef8e60485350e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1575142/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -516025 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1575142/000164033426000718/bdpt_10k.htm#565280 Filing: 000164033426000718 The citation records this snapshot. The page link may show a newer release later.	USD 18,000 Exact value Exact value: 18000 USD 2025-01-01 – 2025-12-31: 18000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · BIOADAPTIVES, INC. · 2025-12-31 BIOADAPTIVES, INC. (edgar:1575142) Capital Expenditure: 18000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T13:14:46Z Snapshot: 19ed27ed0d062779455f6fbc3e021cde2c84c8139c2c05350a9ef8e60485350e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1575142/explain?concept=fundies%3ACapitalExpenditure&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 18000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1575142/000164033426000718/bdpt_10k.htm#569053 Filing: 000164033426000718 The citation records this snapshot. The page link may show a newer release later.	−USD 534,025 Calculation and evidence -516025 − 18000 USD Exact free cash flow: -534025 USD 2025-01-01 – 2025-12-31: -516025 USD · Inspect Operating Cash Flow · Source 2025-01-01 – 2025-12-31: 18000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · BIOADAPTIVES, INC. · 2025-12-31 BIOADAPTIVES, INC. (edgar:1575142) Free cash flow: -534025 USD Concept: free-cash-flow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T13:14:46Z Snapshot: 19ed27ed0d062779455f6fbc3e021cde2c84c8139c2c05350a9ef8e60485350e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1575142?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -516025 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1575142/000164033426000718/bdpt_10k.htm#565280 Filing: 000164033426000718 Input fundies:CapitalExpenditure: 18000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1575142/000164033426000718/bdpt_10k.htm#569053 Filing: 000164033426000718 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

47 filings · 2,259 latest values · 2,259 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001575142, 1575142, BDPT, bdpt, edgar:1575142

Also known as APEX 8 Inc., BIOADAPTIVES, INC., BioAdaptives Inc., BioAdaptives, Inc.

BIOADAPTIVES, INC.

Latest quarter

Revenue

Operating margin

Operating cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2025 2025-01-01 – 2025-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation